Project Grant R01AI187162
Award Date
6/4/25
Completion Date
5/31/30
Dollars Obligated
$800K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $2,688,880 Project Grant to Emory University to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The key products and services to be delivered under this grant include: Comprehensive testing of the effects of IL-15/IL-15RA therapy combined with TGF-beta blockade on different T and NK cell...
This $1,332,155 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to develop optimized immunotherapy strategies for curing HIV in infants. The key objectives are to 1) evaluate the impact of NF-kB pathway activation with broadly neutralizing antibodies (bNAbs) during early antiretroviral therapy (ART) on viral reservoir establishment, 2) assess whether TLR7/8...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $653,693 to Emory University to conduct structural studies of the HIV-1 virus. The research aims to gain a detailed understanding of the molecular mechanisms underlying HIV-1 assembly, maturation, and entry into host cells. The work will leverage advanced cryo-electron microscopy and tomography techniques to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $194,616 to Emory University for the development of virus-like particles (VLPs) to support HIV-1 cure strategies. The key objectives are to: 1) Use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent to reactivate latent HIV-1 proviruses, and 2) Utilize VLPs to deliver the Cas12k enzyme fused to HIV-1...
This $812,810 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Emory University to generate highly differentiated natural killer (NK) cells and evaluate their synergistic effects with broadly neutralizing antibodies in reducing the SIV reservoir and establishing viral control in the absence of antiretroviral therapy (ART). The key objectives are to: 1) define...
This $617,376 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at Emory University to elucidate the timing and regulation of HIV-1 protease (PR) autoactivation and viral maturation. The key products and services to be delivered under this award include: 1) Measuring the timing of PR activation relative to HIV-1 virus particle scission from the host...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $799,017 to Emory University to conduct research on generating highly differentiated natural killer (NK) cells that can synergize with broadly neutralizing antibodies to control viral replication in the absence of antiretroviral therapy (ART). The research aims to: 1) define the function and distribution of NK cells in...
This $775,391 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to investigate the role of the human protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The primary awardee, Vitalant Research Institute, will conduct in vitro studies to elucidate the molecular and immunological mechanisms underlying galectin-9's impact on the HIV reservoir. Additionally,...
This federal Project Grant award of $1,766,954.46 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the immune microenvironments that impact HIV persistence and expression during antiretroviral therapy (ART). The key objectives are to: 1) Determine the location, phenotype, and microenvironment of HIV viral RNA (vRNA)-expressing cells in secondary lymphoid tissues of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $223,300 to Emory University to develop novel antiviral compounds targeting the HIV capsid protein. The primary goals are to synthesize and characterize analogs of lead compounds that can bind and inhibit the HIV capsid, including mutations that confer resistance to the recently approved drug lenacapavir. The...